{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:02:40Z","timestamp":1780293760493,"version":"3.54.0"},"reference-count":229,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a poor prognosis despite advances in treatment strategies. Standard treatment regimens induce remissions in many patients, but relapse occurs in approximately half, highlighting the urgent need for novel therapeutic strategies. Antibody-based therapies have significantly improved the treatment of acute lymphoblastic leukemia (ALL), but progress in AML has been slower, with only gemtuzumab ozogamicin (GO) receiving FDA approval to date. This is largely due to the absence of AML-specific surface antigens and the challenge of distinguishing malignant blasts from normal hematopoietic cells, which raises concerns about on-target\/off-leukemia toxicity. Nonetheless, a wide range of antibody constructs, including unconjugated monoclonal antibodies, antibody-drug conjugates, and bispecific T cell engagers (BTCEs), are now under investigation in both preclinical studies and clinical trials, predominantly in the relapsed\/refractory (R\/R) setting. Encouraging results from early-phase studies suggest that antibody-based approaches could complement or even partially replace traditional cytotoxic regimens in selected patient groups. In this review, we summarize the spectrum of antigenic targets explored for AML immunotherapy, critically assess clinical outcomes achieved so far, and discuss current efforts to improve efficacy, durability, and safety. We also highlight emerging strategies aimed at overcoming antigen heterogeneity and resistance, thereby advancing antibody-based therapies toward broader clinical application in AML.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1803185","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:27:54Z","timestamp":1780291674000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia"],"prefix":"10.3389","volume":"17","author":[{"given":"Milad","family":"Rasouli","sequence":"first","affiliation":[{"name":"Department of Immunology, Erasmus University Medical Center","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Dalem","sequence":"additional","affiliation":[{"name":"Department of Immunology, Erasmus University Medical Center","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.G.P.","family":"Raaijmakers","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC Cancer Institute","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Katsikis","sequence":"additional","affiliation":[{"name":"Department of Immunology, Erasmus University Medical Center","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan J.","family":"Erkeland","sequence":"additional","affiliation":[{"name":"Department of Immunology, Erasmus University Medical Center","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.12703\/p6-96","article-title":"Advances in treating acute myeloid leukemia","volume":"6","author":"Showel","year":"2014","journal-title":"F1000Prime Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-021-10308-6","article-title":"Acute myeloid leukemia stem cells: Origin, characteristics, and clinical implications","volume":"18","author":"Long","year":"2022","journal-title":"Stem Cell Rev Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-23-0202","article-title":"Recent advances in immune-based therapies for acute myeloid leukemia","volume":"5","author":"Restelli","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA: A Cancer J For Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2012.02.011","article-title":"Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays","volume":"526","author":"Golay","year":"2012","journal-title":"Arch Biochem Biophys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbac021","article-title":"The global landscape of approved antibody therapies","volume":"5","author":"Lyu","year":"2022","journal-title":"Antib Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030360","article-title":"Bispecific antibodies and antibody-drug conjugates for cancer therapy: Technological considerations","volume":"10","author":"Shim","year":"2020","journal-title":"Biomolecules"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244181","article-title":"Antibody-based immunotherapies for the treatment of hematologic Malignancies","volume":"16","author":"Jureczek","year":"2024","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4062\/biomolther.2024.146","article-title":"Mechanism of action and pharmacokinetics of approved bispecific antibodies","volume":"32","author":"Choi","year":"2024","journal-title":"Biomolecules Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/life11060465","article-title":"BiTEs, DARTS, BiKEs and TriKEs\u2014are antibody based therapies changing the future treatment of AML","volume":"11","author":"Allen","year":"2021","journal-title":"Life"},{"key":"B14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.21147\/j.issn.1000-9604.2025.04.02","article-title":"Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia","volume":"37","author":"Lin","year":"2025","journal-title":"Chin J Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14983","article-title":"Barriers to antibody therapy in solid tumors, and their solutions","volume":"112","author":"Matsumura","year":"2021","journal-title":"Cancer Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s42003-021-01790-2","article-title":"Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity","volume":"4","author":"Mandrup","year":"2021","journal-title":"Commun Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2531223","article-title":"Innovative Strategies for T Cell Engagers for Cancer Immunotherapy","volume":"17","author":"Bergamaschi","year":"2025","journal-title":"mAbs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1052090","article-title":"The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers","volume":"13","author":"van Diest","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor\u2013modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00262","article-title":"A bump in the road: How the hostile AML microenvironment affects CAR T cell therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"biomark Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-7685","article-title":"CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: Real-world outcomes from a comprehensive cancer center","volume":"146","author":"Hsieh","year":"2025","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-8038","article-title":"Comparative safety profiles of bispecific T-cell engagers and CAR-T therapies: Real-world insights from the FDA adverse event reporting system database","volume":"146","author":"Singh","year":"2025","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061610","article-title":"Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer","volume":"11","author":"Rodr\u00edguez-Nava","year":"2023","journal-title":"Biomedicines"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1211221","article-title":"Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity","volume":"5","author":"Dubrovsky","year":"2016","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123742","article-title":"Acute myeloid leukemia stem cells: The challenges of phenotypic heterogeneity","volume":"12","author":"Arnone","year":"2020","journal-title":"Cancers"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132359","article-title":"The immunotherapy of acute myeloid leukemia: A clinical point of view","volume":"16","author":"Mosna","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/jci129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-3179","article-title":"FDA approval: Gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia","volume":"24","author":"Jen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: Results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0025","article-title":"The EMA review of Mylotarg (Gemtuzumab Ozogamicin) for the treatment of acute myeloid leukemia","volume":"24","author":"Ali","year":"2019","journal-title":"Oncologist"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9670-0","article-title":"Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed\/refractory acute myeloid leukemia","volume":"30","author":"Lapusan","year":"2012","journal-title":"Invest New Drugs"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.274118","article-title":"A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia","volume":"107","author":"Vasu","year":"2022","journal-title":"Haematologica"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281128","article-title":"An open-label, phase I\/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia","volume":"107","author":"Fiedler","year":"2022","journal-title":"Haematologica"},{"key":"B52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2018-99-112891","article-title":"Maturing clinical profile of IMGN779, a next-generation CD33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-002-0034-y","article-title":"Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia","volume":"98","author":"Sekeres","year":"2013","journal-title":"Haematologica"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903050013","article-title":"Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial","volume":"50","author":"Raza","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-841171","article-title":"A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML","volume":"132","author":"Fathi","year":"2018","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0645-z","article-title":"Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents","volume":"34","author":"Kubasch","year":"2020","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","article-title":"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study","volume":"35","author":"Montesinos","year":"2021","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann Hematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2021-153638","article-title":"Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134391","article-title":"A Phase I\/IIa study of Lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): initial phase I results","volume":"136","author":"Qi","year":"2020","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15663","article-title":"Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment","volume":"114","author":"Ikezoe","year":"2023","journal-title":"Cancer Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26136","article-title":"A phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia","volume":"96","author":"Daver","year":"2021","journal-title":"Am J Hematol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): Final analysis from a phase Ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05892-9","article-title":"The clinical efficacy of a daratumumab-based regimen in relapsed\/refractory acute leukemia: a single-center experience","volume":"103","author":"Dai","year":"2024","journal-title":"Ann Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107690","article-title":"Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study","volume":"152","author":"Al Malki","year":"2025","journal-title":"Leuk Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-023-01490-w","article-title":"Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease","volume":"16","author":"Heitmann","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.7059","article-title":"Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia","volume":"33","author":"Sanford","year":"2015","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/blood-2023-185533","article-title":"Final results from phase 1 study of Briquilimab, an anti-CD117 monoclonal antibody, in combination with low dose irradiation and fludarabine conditioning, shows durable remissions in older adults with acute myeloid leukemia in complete remission and myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation","volume":"142","author":"Gandhi","year":"2023","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.tps3156","article-title":"TIP: A phase I\/II study of MGTA-117, an anti-CD117 antibody-drug conjugate, in patients with adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB)","volume":"40","author":"Andrew","year":"2022","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leukemia Lymphoma"},{"key":"B76","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2019-127977","article-title":"Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33\/CD3 BiTE\u00ae(bispecific T-cell engager) in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","volume":"134","author":"Subklewe","year":"2019","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1182\/blood-2019-129042","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2: 2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"134","author":"Westervelt","year":"2019","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13742","article-title":"First-in-human study of JNJ-67571244, a CD33 \u00d7 CD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"17","author":"Narayan","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134576","article-title":"Flotetuzumab as salvage therapy for primary induction failure and early relapse acute myeloid leukemia","volume":"136","author":"Aldoss","year":"2020","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13467","article-title":"First-in-human study of JNJ-63709178, a CD123\/CD3 targeting antibody, in relapsed\/refractory acute myeloid leukemia","volume":"16","author":"Boyiadzis","year":"2023","journal-title":"Clin Transl Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141619","article-title":"Preliminary results from a Phase 1 study of APVO436, a novel anti-CD123 x anti-CD3 bispecific molecule, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"136","author":"Watts","year":"2020","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167468","article-title":"Updated results from a Phase 1 study of APVO436, a novel bispecific anti-CD123 x anti-CD3 Adaptir\u2122 molecule, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"140","author":"Watts","year":"2022","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215287","article-title":"Risk, characteristics and biomarkers of cytokine release syndrome in patients with relapsed\/refractory AML or MDS treated with CD3xCD123 bispecific antibody APVO436","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-134746","article-title":"Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study","volume":"136","author":"Ravandi","year":"2020","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1182\/blood-2023-190693","article-title":"A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-positive AML","volume":"142","author":"Nguyen","year":"2023","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood-2023-187721","article-title":"A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed\/refractory acute myeloid leukemia","volume":"142","author":"Murthy","year":"2023","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000974228.65087.81","article-title":"PB1847: a phase 1 study to investigate cln-049, a flt3\/cd3 bispecific t cell engager, in patients with relapsed\/refractory (r\/r) acute myeloid leukemia (aml) or myelodysplastic syndrome (mds)","volume":"7","author":"Abdul-Hay","year":"2023","journal-title":"HemaSphere"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100110","article-title":"Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Hutchings","year":"2025","journal-title":"Blood Neoplasia"},{"key":"B90","first-page":"98","article-title":"CD123 (interleukin 3 receptor alpha chain)","volume":"15","author":"Moretti","year":"2001","journal-title":"J Biol Regul Homeost Agents"},{"key":"B91","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2015.07.015","article-title":"Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells","volume":"55","author":"Pelosi","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1159\/000480448","article-title":"CD34+CD38-CD123+ cells are present in virtually all acute myeloid leukaemia blasts: a promising single unique phenotype for minimal residual disease detection","volume":"138","author":"Al-Mawali","year":"2017","journal-title":"Acta Haematol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101695","article-title":"Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape","volume":"34","author":"Xie","year":"2023","journal-title":"Transl Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02616-y","article-title":"Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia","volume":"109","author":"Arai","year":"2019","journal-title":"Int J Hematol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01595","article-title":"CD123 expression is associated with high-risk disease characteristics in childhood acute myeloid leukemia: a report from the Children's Oncology Group","volume":"40","author":"Lamble","year":"2022","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci Transl Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010956","article-title":"Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia","volume":"7","author":"Ravandi","year":"2023","journal-title":"Blood Adv"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158029","article-title":"Safety and activity of flotetuzumab in pediatric and young adult patients with relapsed\/refractory acute myeloid leukemia: results from the COG PEPN1812 phase 1 trial","volume":"140","author":"Lamble","year":"2022","journal-title":"ASH"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2023-173162","article-title":"First-in-human study of the CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia: updated safety, efficacy, pharmacokinetics and pharmacodynamics","volume":"142","author":"Bajel","year":"2023","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/mp.a002870.01","article-title":"CD47 (Cluster of differentiation 47)","volume":"25","author":"Kaur","year":"2021","journal-title":"Atlas Genet Cytogenet Oncol Haematol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070","article-title":"CD47-SIRP\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immunooncol Technol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15397","article-title":"The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia","volume":"59","author":"Brierley","year":"2019","journal-title":"Transfusion"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.4.1762","article-title":"Characterization of the human CD27 ligand, a novel member of the TNF gene family","volume":"152","author":"Hintzen","year":"1994","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J Exp Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2024-199634","article-title":"PF-08046040 (SEA-CD70), a nonfucosylated CD70-directed antibody, in combination with azacitidine for patients with myelodysplastic syndromes (MDS): A phase 1 dose-finding and dose expansion study","volume":"144","author":"Grieselhuber","year":"2024","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/toxsci\/kfac052","article-title":"Characterization of an anti-CD70 half-life extended bispecific t-cell engager (HLE-BiTE) and associated on-target toxicity in cynomolgus monkeys","volume":"189","author":"Harper","year":"2022","journal-title":"Toxicol Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"Silva","year":"2025","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m313127200","article-title":"Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes","volume":"279","author":"Marshall","year":"2004","journal-title":"J Biol Chem"},{"key":"B116","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11063","article-title":"Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1","volume":"7","author":"Darwish","year":"2016","journal-title":"Oncotarget"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker","volume":"108","author":"Jan","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.06.033","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1195535","article-title":"The immune receptor Tim-3 acts as a trafficker in a Tim-3\/galectin-9 autocrine loop in human myeloid leukemia cells","volume":"5","author":"Gon\u00e7alves Silva","year":"2016","journal-title":"Oncoimmunology"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15042","article-title":"TIM-3 in normal and Malignant hematopoiesis: Structure, function, and signaling pathways","volume":"112","author":"Kikushige","year":"2021","journal-title":"Cancer Sci"},{"key":"B124","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3892\/ol.2021.12587","article-title":"Expression of immune check point gene TIM-3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome","volume":"21","author":"Kamal","year":"2021","journal-title":"Oncol Lett"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5549","article-title":"Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia","volume":"12","author":"Wu","year":"2023","journal-title":"Cancer Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121632","article-title":"CD38 expression by myeloma cells and its role in the context of bone marrow microenvironment: Modulation by therapeutic agents","volume":"8","author":"Costa","year":"2019","journal-title":"Cells"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02301","article-title":"Immunophenotypic significance of the \"lymphoid\" CD38 antigen in myeloid blood Malignancies","volume":"40","author":"Marinov","year":"1993","journal-title":"Neoplasma"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/s0145-2126(99)00147-2","article-title":"Increased CD38 expression is associated with favorable prognosis in adult acute leukemia","volume":"24","author":"Keyhani","year":"2000","journal-title":"Leuk Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0027","article-title":"Analysis of immunophenotypes and expressions of non-myeloid antigens in acute myeloid leukemia","volume":"40","author":"Wang","year":"2020","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192757","article-title":"CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"104","author":"Naik","year":"2019","journal-title":"Haematologica"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.499","article-title":"FLT3 in lineage specification and plasticity","volume":"3","author":"Greenblatt","year":"2012","journal-title":"Oncotarget"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol Rev"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v87.3.1089.bloodjournal8731089","article-title":"Expression of the hematopoietic growth factor receptor FLT3 (STK-1\/Flk2) in human leukemias","volume":"87","author":"Carow","year":"1996","journal-title":"Blood"},{"key":"B135","article-title":"Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and Malignant hematopoietic cells","volume":"10","author":"Rosnet","year":"1996","journal-title":"Leukemia"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22859","article-title":"FLT3, a prognostic biomarker for acute myeloid leukemia (AML): Quantitative monitoring with a simple anti-FLT3 interaction and flow cytometric method","volume":"33","author":"Ampasavate","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"B139","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-19-1093","article-title":"Characterization of a novel FLT3 BiTE molecule for the treatment of acute myeloid leukemia","volume":"19","author":"Brauchle","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158452","article-title":"The race is on: BiTE vs CART as FLT3-directed immunotherapies in AML","volume":"140","author":"Rohrbacher","year":"2022","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.174.1.63","article-title":"Expression and function of c-kit in hemopoietic progenitor cells","volume":"174","author":"Ogawa","year":"1991","journal-title":"J Exp Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v90.4.1345","article-title":"Stem cell factor and hematopoiesis","volume":"90","author":"Broudy","year":"1997","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1182\/blood-2019-127100","article-title":"CD117 expression is associated with cytogenetic and molecular profiles and outcome in pediatric acute myeloid leukemia","volume":"134","author":"Tarlock","year":"2019","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-022-08000-0","article-title":"The prognostic role of C-KIT, TET1 and TET2 gene expression in acute myeloid leukemia","volume":"50","author":"Nabil","year":"2023","journal-title":"Mol Biol Rep"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6010031","article-title":"CD117\/c-kit in cancer stem cell-mediated progression and therapeutic resistance","volume":"6","author":"Foster","year":"2018","journal-title":"Biomedicines"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/nature10783","article-title":"Endothelial and perivascular cells maintain haematopoietic stem cells","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031858","article-title":"Nonmyeloablative conditioning combined with anti-CD117 antibody Briquilimab in older adults with high-risk AML and MDS","author":"Muffly","year":"2026","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011888","article-title":"Immunotherapy for rapid bone marrow conditioning and leukemia depletion that allows efficient hematopoietic stem cell transplantation","volume":"13","author":"Dal Collo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70055","article-title":"A single\u2010chain variable fragment\u2010based bispecific T\u2010cell activating antibody against CD117 enables T\u2010cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"8","author":"Volta","year":"2024","journal-title":"Hemasphere"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-837468","article-title":"Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis","volume":"132","author":"Pronier","year":"2018","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nrc1696","article-title":"Wilms' tumour: connecting tumorigenesis and organ development in the kidney","volume":"5","author":"Rivera","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166323","article-title":"Prognostic impact of WT1 mutation on AML of different risk groups based on 2022 European Leukemianet (ELN) risk classification","volume":"140","author":"Pan","year":"2022","journal-title":"Blood"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-262543","article-title":"Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"116","author":"Becker","year":"2010","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404752","article-title":"The Wilms\u2019 tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis","volume":"21","author":"Hosen","year":"2007","journal-title":"Leukemia"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402434","article-title":"The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia","volume":"16","author":"Karakas","year":"2002","journal-title":"Leukemia"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v90.3.1217","article-title":"High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome","volume":"90","author":"Bergmann","year":"1997","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123306","article-title":"The role of wilms\u2019 tumor gene (WT1) expression as a marker of minimal residual disease in acute myeloid leukemia","volume":"11","author":"Lazzarotto","year":"2022","journal-title":"J Clin Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02520-x","article-title":"Immunotherapy targeting a leader sequence cathepsin G-derived peptide","volume":"39","author":"Shi","year":"2025","journal-title":"Leukemia"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.11.013","article-title":"Targeting HLA-DR loss in hematologic Malignancies with an inhibitory chimeric antigen receptor","volume":"30","author":"Fei","year":"2022","journal-title":"Mol Ther"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1627161","article-title":"Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00018-024-05410-0","article-title":"A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia","volume":"81","author":"Zeng","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160209","article-title":"Preclinical characterization of NGM936, a novel bispecific T cell engager targeting ILT3 for the treatment of acute myeloid leukemia with monocytic differentiation","volume":"140","author":"Lin","year":"2022","journal-title":"Blood"},{"key":"B164","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-024-01586-x","article-title":"IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011858","article-title":"Dual-targeting CD33\/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile","volume":"8","author":"Zeng","year":"2024","journal-title":"Blood Adv"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013212","article-title":"Targeting CD38 with isatuximab and a novel CD38\/CD3\u00d7 CD28 trispecific T-cell engager in older patients with acute myeloid leukemia","volume":"8","author":"Mart\u00edn-S\u00e1nchez","year":"2024","journal-title":"Blood Adv"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2022-6313","article-title":"Evaluation of a dual CD123-FLT3 BiTE molecule for acute myeloid leukemia","volume":"82","author":"Goldstein","year":"2022","journal-title":"Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164113","article-title":"A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2174015","article-title":"Biological therapy in elderly patients with acute myeloid leukemia","volume":"23","author":"Ciotti","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1374963","article-title":"Updates in novel immunotherapeutic strategies for relapsed\/refractory AML","volume":"14","author":"Bawek","year":"2024","journal-title":"Front Oncol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S205678","article-title":"IFN-\u03b3 and TNF-\u03b1 aggravate endothelial damage caused by CD123-targeted CAR T cell","volume":"12","author":"Sun","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.02.016","article-title":"Current strategies in extending half-lives of therapeutic proteins","volume":"301","author":"Zaman","year":"2019","journal-title":"J Controlled Release"},{"key":"B173","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1007\/s12170-020-00661-5","article-title":"CAR T cell and BiTE therapy\u2014new therapies, new risks","volume":"15","author":"Chen","year":"2021","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"B175","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1182\/hematology.2023000455","article-title":"Novel immunotherapies in the treatment of AML: is there hope","volume":"2023","author":"Subklewe","year":"2023","journal-title":"Hematology"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03439-x","article-title":"CD33 BiTE(\u00ae) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells","volume":"72","author":"Marcinek","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B178","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/jco.20.00475","article-title":"Immune biology of acute myeloid leukemia: implications for immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J Clin Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061410","article-title":"Targeting the tumor microenvironment in acute myeloid leukemia: the future of immunotherapy and natural products","volume":"10","author":"Hino","year":"2022","journal-title":"Biomedicines"},{"key":"B180","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00262-023-03594-1","article-title":"Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8(+)\u2009clonal effector and CAR T-cell function while promoting a senescence-associated phenotype","volume":"73","author":"Towers","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B181","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41408-020-0331-4","article-title":"Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment","volume":"10","author":"Nair-Gupta","year":"2020","journal-title":"Blood Cancer J"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01314-y","article-title":"NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia","volume":"23","author":"Witkowski","year":"2022","journal-title":"Nat Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"B186","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1038\/s41467-025-58868-2","article-title":"IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell Malignancies","volume":"16","author":"Domizi","year":"2025","journal-title":"Nat Commun"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23074019","article-title":"Lineage conversion in pediatric B-cell precursor acute leukemia under blinatumomab therapy","volume":"23","author":"Semchenkova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021680","article-title":"CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia","volume":"144","author":"Mazziotta","year":"2024","journal-title":"Blood"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100004","article-title":"Comprehensive profiling of AML and T-cell states across disease stages in acute myeloid leukemia using spectral flow cytometry","volume":"1","author":"Yassouf","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","volume":"107","author":"Stein-Merlob","year":"2021","journal-title":"Heart"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003766","article-title":"JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy","volume":"10","author":"Leclercq","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v128.22.652.652","article-title":"Ruxolitinib prevents cytokine release syndrome after CART cell therapy without impairing the anti-tumor effect in a xenograft model","volume":"128","author":"Kenderian","year":"2016","journal-title":"Blood"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2022-167715","article-title":"The dual PI3K\u03b4\u03b3 inhibitor duvelisib potently inhibits IL-6 production and cytokine release syndrome (CRS) while maintaining CAR-T function in vitro and in vivo","volume":"136","author":"Amatya","year":"2020","journal-title":"Blood"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br J Cancer"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00446","article-title":"Perspective: designing T-cell engagers with better therapeutic windows","volume":"10","author":"Vafa","year":"2020","journal-title":"Front Oncol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"14397","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci Rep"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.241877","article-title":"The biodistribution of a CD3 and EpCAM bispecific T-cell engager is driven by the CD3 arm","volume":"61","author":"Suurs","year":"2020","journal-title":"J Nucl Med"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002582","article-title":"Src\/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies","volume":"9","author":"Leclercq","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2022.2083479","article-title":"Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors","volume":"11","author":"Leclercq","year":"2022","journal-title":"Oncoimmunology"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2166786","article-title":"Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS)","volume":"23","author":"Leclercq-Cohen","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"B203","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v126.23.1798.1798","article-title":"Tuning T cell affinity improves efficacy and safety of anti-CD38\u00d7 anti-CD3 bispecific antibodies in monkeys-a potential therapy for multiple myeloma","volume":"126","author":"Moore","year":"2015","journal-title":"Blood"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2334336100","article-title":"Lytic versus stimulatory synapse in cytotoxic T lymphocyte\/target cell interaction: manifestation of a dual activation threshold","volume":"100","author":"Faroudi","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/ni1058","article-title":"T cell killing does not require the formation of a stable mature immunological synapse","volume":"5","author":"Purbhoo","year":"2004","journal-title":"Nat Immunol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"MAbs"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2025.2522088","article-title":"The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple","volume":"20","author":"Abdelmotaleb","year":"2025","journal-title":"Expert Opin Drug Discov"},{"key":"B209","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/abt\/tbab009","article-title":"An optimal antitumor response by a novel CEA\/CD3 bispecific antibody for colorectal cancers","volume":"4","author":"Wang","year":"2021","journal-title":"Antibody Ther"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-0657","article-title":"Relative target affinities of T-cell\u2013dependent bispecific antibodies determine biodistribution in a solid tumor mouse model","volume":"17","author":"Mandikian","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2189974","article-title":"Structure-based engineering of a novel CD3\u03f5-targeting antibody for reduced polyreactivity","volume":"15","author":"Liu","year":"2023","journal-title":"MAbs"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0844-y","article-title":"Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen","volume":"59","author":"Bluemel","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2425781122","article-title":"Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency","volume":"122","author":"Leithner","year":"2025","journal-title":"Proc Natl Acad Sci"},{"key":"B214","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41375-023-02127-0","article-title":"Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment","volume":"38","author":"H\u00e4nel","year":"2024","journal-title":"Leukemia"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell\u2013mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139625","article-title":"Venetoclax enhances anti-leukemia activity of CD123-specific BiTE-secreting T-cells in AML","volume":"136","author":"Mu-Mosley","year":"2020","journal-title":"Blood"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-03047-w","article-title":"Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis","volume":"113","author":"Kobayashi","year":"2021","journal-title":"Int J Hematol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab","volume":"8","author":"K\u00f6hnke","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1671-y","article-title":"CEA\/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1","volume":"64","author":"Osada","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0000000000000061","article-title":"Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation","volume":"20","author":"Sanmamed","year":"2014","journal-title":"Cancer J"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019961","article-title":"Escape from T-cell\u2013targeting immunotherapies in acute myeloid leukemia","volume":"143","author":"Vadakekolathu","year":"2024","journal-title":"Blood"},{"key":"B222","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1182\/blood-2019-125966","article-title":"A phase 1 study of Flotetuzumab, a CD123 x CD3 DART\u00ae protein, combined with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory acute myeloid leukemia","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026934","article-title":"STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia","volume":"145","author":"Linder","year":"2025","journal-title":"Blood"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd1524","article-title":"Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell\u2013cold solid tumors","volume":"13","author":"Belmontes","year":"2021","journal-title":"Sci Transl Med"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32028","article-title":"Targeting the arginine metabolic brake enhances immunotherapy for leukaemia","volume":"145","author":"Mussai","year":"2019","journal-title":"Int J Cancer"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02387-4","article-title":"Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse","volume":"38","author":"Kazerani","year":"2024","journal-title":"Leukemia"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-25-0535","article-title":"Conditionally active CD28xVISTA bispecific antibodies promote myeloid-driven T-cell activation","volume":"13","author":"Thisted","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B228","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/abt\/tbad027","article-title":"Next generation of multispecific antibody engineering","volume":"7","author":"Keri","year":"2024","journal-title":"Antibody Ther"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1803185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:27:57Z","timestamp":1780291677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1803185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":229,"alternative-id":["10.3389\/fimmu.2026.1803185"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1803185","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"1803185"}}